ARPC1A

Across TCGA pan-cancer cohorts, ARPC1A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ARPC1A data layer compared with 29 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ARPC1A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ARPC1A expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where ARPC1A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.651	0.425	.018	10	view →
LSCC	OS	Median	All	1.000	0.922	.008	8	view →
HNSC	DFS	Tertile	III,IV	0.918	0.708	.021	8	view →
OV	DFS	Median	All	0.859	1.000	.032	4	view →
CCRCC	DFS	Median	III,IV	0.728	0.424	.016	4	view →
GBM	OS	Median	All	0.631	0.456	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ARPC1A–PDAC (OS)

Open the PDAC breakdown →